VERA Quote, Financials, Valuation and Earnings

Arvinas has a net margin of -- compared to Vera Therapeutics's net margin of 43.91%. Vera Therapeutics's return on equity of -- beat Arvinas's return on equity of -7.72%.

Vera Therapeutics has a consensus price target of $63.36, signalling upside risk potential of 203.73%. On the other hand Arvinas has an analysts' consensus of $19.36 which suggests that it could grow by 161.64%. Given that Vera Therapeutics has higher upside potential than Arvinas, analysts believe Vera Therapeutics is more attractive than Arvinas.

Vera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Arvinas has a beta of 2.192, suggesting its more volatile than the S&P 500 by 119.176%.

Vera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vera Therapeutics pays -- of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

Vera Therapeutics quarterly revenues are --, which are smaller than Arvinas quarterly revenues of $188.8M. Vera Therapeutics's net income of -$51.7M is lower than Arvinas's net income of $82.9M. Notably, Vera Therapeutics's price-to-earnings ratio is -- while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics is -- versus 1.25x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Vera Therapeutics's net margin of -49.65%. Vera Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Vera Therapeutics has a consensus price target of $63.36, signalling upside risk potential of 203.73%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 49.12%. Given that Vera Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Vera Therapeutics is more attractive than NovaBay Pharmaceuticals.

Vera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

Vera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vera Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Vera Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Vera Therapeutics's net income of -$51.7M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Vera Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Vera Therapeutics's net margin of 21.63%. Vera Therapeutics's return on equity of -- beat Pfizer's return on equity of 8.72%.

Vera Therapeutics has a consensus price target of $63.36, signalling upside risk potential of 203.73%. On the other hand Pfizer has an analysts' consensus of $29.24 which suggests that it could grow by 21.68%. Given that Vera Therapeutics has higher upside potential than Pfizer, analysts believe Vera Therapeutics is more attractive than Pfizer.

Vera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.572, suggesting its less volatile than the S&P 500 by 42.759%.

Vera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.08% to investors and pays a quarterly dividend of $0.43 per share. Vera Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Vera Therapeutics quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $13.7B. Vera Therapeutics's net income of -$51.7M is lower than Pfizer's net income of $3B. Notably, Vera Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics is -- versus 2.19x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Instil Bio has a net margin of -- compared to Vera Therapeutics's net margin of --. Vera Therapeutics's return on equity of -- beat Instil Bio's return on equity of --.

Vera Therapeutics has a consensus price target of $63.36, signalling upside risk potential of 203.73%. On the other hand Instil Bio has an analysts' consensus of $118.67 which suggests that it could grow by 328.4%. Given that Instil Bio has higher upside potential than Vera Therapeutics, analysts believe Instil Bio is more attractive than Vera Therapeutics.

Vera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Instil Bio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Vera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Instil Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vera Therapeutics pays -- of its earnings as a dividend. Instil Bio pays out -- of its earnings as a dividend.

Vera Therapeutics quarterly revenues are --, which are smaller than Instil Bio quarterly revenues of --. Vera Therapeutics's net income of -$51.7M is lower than Instil Bio's net income of -$28.2M. Notably, Vera Therapeutics's price-to-earnings ratio is -- while Instil Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics is -- versus -- for Instil Bio. Usually stocks with elevated PS ratios are considered overvalued.